Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genmab ( (GMAB) ) has provided an update.
Genmab A/S, a Denmark-based biotechnology company listed on Nasdaq as GMAB, develops antibody-based therapeutics with a primary focus on oncology and serious diseases, and its stock is closely watched by global life sciences investors. The company routinely uses share-based compensation such as restricted stock units to incentivize and retain senior executives, under a governance framework shaped by European market abuse and disclosure rules.
On April 1, 2026, Genmab reported the vesting of restricted stock units in the form of share acquisitions outside the market by President and CEO Jan van de Winkel, Executive Vice President and CFO Anthony Pagano, and Executive Vice President and Chief Strategy Officer Martine van Vugt. The transactions, carried out at a reference price of DKK 1,758.50 per share and stemming from grants made on March 29, 2023, increase direct equity holdings of top management and signal continued alignment between Genmab’s leadership and shareholders while fulfilling regulatory transparency requirements for insider dealings.
The most recent analyst rating on (GMAB) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a Denmark-based biotechnology company listed on Nasdaq under the ticker GMAB, focused on the development of antibody-based therapies, primarily in oncology and related serious diseases. The company is a significant player in the European biopharmaceutical sector, and its shares are actively followed by international investors given its late-stage pipeline and partnered products.
Genmab regularly uses equity-based incentives, including restricted stock units, to align the interests of its senior management with those of shareholders and to retain key talent in a competitive life sciences labor market. Disclosures of management dealings in company shares are subject to European market abuse regulations, making such announcements an important source of transparency for stakeholders tracking insider ownership and governance practices.
Average Trading Volume: 1,763,501
Technical Sentiment Signal: Sell
Current Market Cap: $16.34B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.